PHATPhathom Pharmaceuticals, Inc.
$7.12-34% 1Y
$7.12
$6.7252 weeks$18.08
PHAT in its own filings
PHAT's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
166
Events found in the filings · across 490 filings · the record starts in 2019
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 29, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 23, 2019
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 29, 2026
- Delisting notice / listing-rule failurehistorical
- 2019-12-02
- SEC comment-letter activity12 occurrences
- 2024-06-25
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 29, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive …Other event · Form 8-K
- Jul 30, 2026Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 23, 2026On June 23, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA ® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (“EoE”) in adults.Other event · Form 8-K
- Apr 30, 2026Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Feb 26, 2026Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance.Earnings release · press release
- Jan 8, 2026On January 7, 2026, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to …Other event · Form 8-K
- Jan 7, 2026Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Nov 4, 2025On November 4, 2025, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 clinical trial evaluating VOQUEZNA ® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (“EoE”) in adults.Other event · Form 8-K
- Oct 30, 2025Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
- Oct 27, 2025On October 25, 2025, Phathom Pharmaceuticals, Inc. (“Phathom” or the “Company”) announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA ® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease (“NERD”) have been published in the American Journal of …Other event · Form 8-K
- Oct 6, 2025Effective October 6, 2025, Sanjeev Narula was appointed as the Chief Financial and Business Officer of Phathom Pharmaceuticals, Inc. (the “Company”)Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…